<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4432">
  <stage>Registered</stage>
  <submitdate>7/05/2014</submitdate>
  <approvaldate>7/05/2014</approvaldate>
  <nctid>NCT02134834</nctid>
  <trial_identification>
    <studytitle>A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595</studytitle>
    <scientifictitle>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of OP0595 Administered Intravenously in Healthy Male Subjects.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>OP0595-1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteers</healthcondition>
    <healthcondition>Bacterial Infections</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - OP0595
Treatment: drugs - Placebo

Experimental: Ascending single dose of OP0595 - 

Placebo Comparator: Normal Saline - 


Treatment: drugs: OP0595
Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation

Treatment: drugs: Placebo
Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety from baseline through the end of the study - Number of patients with adverse events</outcome>
      <timepoint>Day 1 to Day 7</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma PK parameters of OP0595 and its metabolites - Cmax, tmax, AUC0-last, AUC0-inf, Kel, T1/2, CLtot, Vdss</outcome>
      <timepoint>Day 1 to Day 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urine PK parameters of OP0595 and its metabolites - Ae, Ae0-t, Ae0-t/Dose, CLr</outcome>
      <timepoint>Day 1 to Day 2</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Caucasian males aged between 18 and 45 years (inclusive) at Screening

          -  A Body Mass Index (BMI) between 18.0 and 30.0 kg/mÂ² (inclusive) at Screening

          -  Good general health as determined by the Investigator based on medical history,
             physical examination, vital signs, 12-lead ECG and clinical laboratory tests

          -  Negative urine test for drugs of abuse and breath test for alcohol both at Screening
             and Day -1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Receipt of any investigational agent or drug within four months before Screening

          -  A history or current evidence of allergic symptoms such as bronchial asthma,
             drug-induced rash or urticaria

          -  Hypersensitivity and/or allergy to drugs

          -  Concurrent or history of clinically significant cardiovascular, hepatic, renal,
             endocrine, gastrointestinal, respiratory, psychiatric, neurologic and/or hematological
             disorders

          -  A history of chronic or recurrent infections or current active infection

          -  A recent history of surgery within three months prior to Screening, determined by the
             Investigator to be clinically relevant

          -  A history or presence of malignancy

          -  Donation of blood (or loss of blood) greater than 400 ml within three months before
             Screening

          -  A history of smoking at any time within one year before Screening</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital> - Perth,</hospital>
    <postcode> - Perth,</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Meiji Seika Pharma Co., Ltd.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objectives of this study are to assess the safety, tolerability and pharmacokinetic
      profile of OP0595 administered intravenously to healthy male, Caucasian, adult subjects at
      single escalating doses.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02134834</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mitsuharu Egawa</name>
      <address>Meiji Seika Pharma Co., Ltd.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>